{"Abstract": [0], "Objective": [1], "To": [2], "evaluate": [3], "the": [4, 143, 162, 181, 205, 236, 269, 325, 329, 360], "comparative": [5], "efficacy": [6], "and": [7, 20, 32, 48, 76, 103, 114, 128, 155, 190, 203, 280, 301, 342], "safety": [8, 304, 368], "of": [9, 39, 44, 89, 165, 188, 252, 271, 294], "glucagon-like": [10], "peptide-1": [11], "receptor": [12], "agonists": [13], "(GLP-1RAs)": [14], "on": [15], "glycaemic": [16, 211, 335], "control,": [17], "body": [18], "weight,": [19], "lipid": [21], "profile": [22], "in": [23, 134, 235, 267, 316], "adults": [24, 67, 318], "with": [25, 68, 79, 85, 95, 145, 226, 232, 319, 324, 357, 373], "type": [26, 69, 227, 320, 354], "2": [27, 70, 228, 321, 355], "diabetes.": [28, 229, 322], "Design": [29], "Systematic": [30, 381], "review": [31, 382], "network": [33, 136], "meta-analysis.": [34], "Data": [35], "sources": [36], "PubMed,": [37], "Web": [38], "Science,": [40], "Cochrane": [41], "Central": [42], "Register": [43], "Controlled": [45], "Trials": [46, 94], "(CENTRAL),": [47], "Embase": [49], "from": [50], "database": [51], "inception": [52], "to": [53, 142, 177, 198, 217, 221, 248, 260, 278, 286], "19": [54], "August": [55], "2023.": [56], "Eligibility": [57], "criteria": [58], "for": [59, 210, 224, 308, 334, 353, 362, 370], "selecting": [60], "studies": [61, 100, 116], "Eligible": [62], "randomised": [63], "controlled": [64], "trials": [65, 123], "enrolled": [66], "diabetes": [71], "who": [72], "received": [73], "GLP-1RA": [74, 83, 102, 126, 208, 332], "treatments": [75], "compared": [77], "effects": [78], "placebo": [80, 109], "or": [81], "any": [82], "drug,": [84], "a": [86, 96, 108], "follow-up": [87], "duration": [88], "at": [90], "least": [91], "12": [92], "weeks.": [93], "crossover": [97], "design,": [98], "non-inferiority": [99], "comparing": [101], "other": [104], "drug": [105, 209, 333], "classes": [106], "without": [107], "group,": [110], "using": [111], "withdrawn": [112], "drugs,": [113], "non-English": [115], "were": [117, 132, 215], "deemed": [118], "ineligible.": [119], "Results": [120], "76": [121], "eligible": [122], "involving": [124], "15": [125, 148], "drugs": [127], "39": [129], "246": [130], "participants": [131], "included": [133], "this": [135, 289], "meta-analysis;": [137], "all": [138], "subsequent": [139], "estimates": [140], "refer": [141], "comparison": [144], "placebo.": [146], "All": [147], "GLP-1RAs": [149, 214, 313, 347], "effectively": [150], "lowered": [151], "haemoglobin": [152, 166, 339], "A": [153, 167, 340], "1c": [154, 168, 341], "fasting": [156, 191, 343], "plasma": [157, 192, 344], "glucose": [158, 193, 345], "concentrations.": [159, 346], "Tirzepatide": [160], "induced": [161, 298], "largest": [163], "reduction": [164], "concentrations": [169, 194], "(mean": [170, 240], "difference": [171, 241], "\u22122.10%": [172], "(95%": [173, 244], "confidence": [174, 187, 245, 251], "interval": [175, 246], "\u22122.47%": [176], "\u22121.74%),": [178], "surface": [179], "under": [180], "cumulative": [182], "ranking": [183], "curve": [184], "94.2%;": [185], "high": [186, 201, 250, 262, 309, 374], "evidence),": [189, 253], "(\u22123.12": [195], "mmol/L": [196, 276, 284], "(\u22123.59": [197], "\u22122.66),": [199], "97.2%;": [200], "confidence),": [202], "proved": [204], "most": [206, 330], "effective": [207, 266, 331], "control.": [212], "Furthermore,": [213], "shown": [216], "have": [218], "strong": [219], "benefits": [220], "weight": [222, 238, 351, 363], "management": [223, 352], "patients": [225], "CagriSema": [230, 358], "(semaglutide": [231], "cagrilintide)": [233], "resulted": [234], "highest": [237], "loss": [239], "\u221214.03": [242], "kg": [243, 258], "\u221217.05": [247], "\u221211.00);": [249], "followed": [254], "by": [255, 299, 337], "tirzepatide": [256, 327], "(\u22128.47": [257], "(\u22129.68": [259], "\u22127.26);": [261], "confidence).": [263], "Semaglutide": [264], "was": [265, 328], "lowering": [268], "concentration": [270], "low": [272], "density": [273], "lipoprotein": [274], "(\u22120.16": [275], "(\u22120.30": [277], "\u22120.02))": [279], "total": [281], "cholesterol": [282], "(\u22120.48": [283], "(\u22120.84": [285], "\u22120.11)).": [287], "Moreover,": [288], "study": [290], "also": [291, 348], "raises": [292], "awareness": [293], "gastrointestinal": [295, 378], "adverse": [296, 379], "events": [297], "GLP-1RAs,": [300, 371], "concerns": [302, 369], "about": [303], "are": [305, 314], "especially": [306, 372], "warranted": [307], "dose": [310, 375], "administration.": [311], "Conclusions": [312], "efficacious": [315], "treating": [317], "Compared": [323], "placebo,": [326], "control": [336], "reducing": [338], "significantly": [349], "improved": [350], "diabetes,": [356], "performing": [359], "best": [361], "loss.": [364], "The": [365], "results": [366], "prompt": [367], "administration,": [376], "regarding": [377], "events.": [380], "registration": [383], "PROSPERO": [384], "CRD42022342845.": [385]}